While studying how bio-inspired materials might inform the design of next-generation computers, scientists at ORNL achieved a first-of-its-kind result that could have big implications for both edge computing and human health.
Although blockchain is best known for securing digital currency payments, researchers at the Department of Energy’s Oak Ridge National Laboratory are using it to track a different kind of exchange: It’s the first time blockchain has ever been used to validate communication among devices on the electric grid.
Laboratory Director Thomas Zacharia presented five Director’s Awards during Saturday night's annual Awards Night event hosted by UT-Battelle, which manages ORNL for the Department of Energy.
Over the past seven years, researchers in ORNL’s Geospatial Science and Human Security Division have mapped and characterized all structures within the United States and its territories to aid FEMA in its response to disasters. This dataset provides a consistent, nationwide accounting of the buildings where people reside and work.
ORNL scientists will present new technologies available for licensing during the annual Technology Innovation Showcase. The event is 9 a.m. to 3 p.m. Thursday, June 16, at the Manufacturing Demonstration Facility at ORNL’s Hardin Valley campus.
Three ORNL scientists have been elected fellows of the American Association for the Advancement of Science, or AAAS, the world’s largest general scientific society and publisher of the Science family of journals.
Oak Ridge National Laboratory will give college students the chance to practice cybersecurity skills in a real-world setting as a host of the Department of Energy’s fifth collegiate CyberForce Competition on Nov. 16. The event brings together student teams from across the country to compete at 10 of DOE’s national laboratories.
IDEMIA Identity & Security USA has licensed an advanced optical array developed at Oak Ridge National Laboratory. The portable technology can be used to help identify individuals in challenging outdoor conditions.
OAK RIDGE, Tenn., March 20, 2019—Direct observations of the structure and catalytic mechanism of a prototypical kinase enzyme—protein kinase A or PKA—will provide researchers and drug developers with significantly enhanced abilities to understand and treat fatal diseases and neurological disorders such as cancer, diabetes, and cystic fibrosis.